N-Acetyl Semax (Na Semax) is a synthetic, N-terminally acetylated analog of Semax, derived from the adrenocorticotropic hormone fragment ACTH(4-10). In laboratory research, it is investigated for its stability, enhanced resistance to enzymatic degradation, BDNF-pathway modulation, and neurotrophic signaling under hypoxic or metabolic cellular stress.
N-Acetyl Semax (Na Semax) is a synthetic, N-terminally acetylated analog of Semax, derived from the adrenocorticotropic hormone fragment ACTH(4-10). In laboratory research, it is investigated for its stability, enhanced resistance to enzymatic degradation, BDNF-pathway modulation, and neurotrophic signaling under hypoxic or metabolic cellular stress.
N-Acetyl Semax, frequently designated as Na Semax, represents a structural modification of the synthetic heptapeptide Semax. The baseline sequence of Semax—Met-Glu-His-Phe-Pro-Gly-Pro—is structurally rooted in the ACTH(4-10) core sequence, which retains biological activity without eliciting endocrine or steroidogenic effects associated with full-length adrenocorticotropic hormone.
The defining modification in Na Semax is the addition of an acetyl group (CH3CO-) to the N-terminal methionine residue. In organic chemistry and peptide synthesis, N-terminal acetylation eliminates the positive charge of the free amine, converting it into a neutral amide function. This structural alteration alters the polar surface area of the molecule, enhances lipophilicity, and provides steric protection against exopeptidase-mediated cleavage, specifically targeting aminopeptidases present in biofluids and extracellular media.
Researchers studying Na Semax utilize this acetylated variant to evaluate whether resistance to terminal degradation translates to sustained receptor binding and prolonged signal transduction in primary neuronal cultures, hippocampal slice preparations, and animal models of central nervous system (CNS) stress.
The primary focus of empirical inquiry surrounding Na Semax centers on its capacity to modulate trophic factor expression within central and peripheral neuronal tissues. Preclinical in vitro assays suggest that exposure to ACTH(4-10) regulatory peptide analogs upregulates the transcription and translation of Brain-Derived Neurotrophic Factor (BDNF) and its cognate receptor, Tropomyosin receptor kinase B (TrkB).
At the cellular level, the activation of the BDNF/TrkB axis initiates downstream intracellular signaling cascades, most notably the Ras/MAPK, PI3K/Akt, and PLCγ pathways. These cascades govern gene expression patterns responsible for synaptic plasticity, dendritic spine remodeling, and neuronal survival. Experimental data indicates that Na Semax alters transcriptional regulators like CREB (cAMP response element-binding protein), thereby influencing cellular adaptation to environmental insults.
Additionally, non-clinical models demonstrate that Na Semax influences neurotrophin-3 (NT-3) and Nerve Growth Factor (NGF) gene expression profiles. Investigations logged in the PX1 research library highlight how N-terminal acetylation preserves structural signaling integrity during prolonged incubation periods, offering researchers a stable tool to measure sustained neurotrophic activation.
In vitro and animal models of cerebral ischemia, oxygen-glucose deprivation (OGD), and neurotoxicity serve as primary research frameworks for evaluating Na Semax. When neuronal cell cultures or rodent tissue sections are subjected to hypoxic conditions, acute cellular injury occurs via excitotoxicity, oxidative stress, and inflammatory signaling cascades.
Preclinical studies indicate that treatment with Na Semax during or immediately following metabolic stress preserves mitochondrial membrane potential and diminishes the expression of pro-apoptotic markers, such as caspase-3 and Bax. Concurrently, upregulated expression of anti-apoptotic signaling molecules like Bcl-2 has been documented in treated cultures.
Furthermore, rodent models assessing focal ischemic injury demonstrate that administration of ACTH-derived peptides correlates with a reduction in microglial activation and a localized decrease in pro-inflammatory cytokines, including TNF-alpha, IL-1 beta, and IL-6. This multi-target mechanism makes Na Semax a key candidate for examining cerebrovascular protection and post-ischemic tissue recovery.
To establish rigorous experimental controls, investigators frequently contrast Na Semax with other regulatory ACTH derivatives and nootropic peptide analogs. The most relevant comparisons include unmodified Semax, C-terminally modified Semax Amidate, and structurally distinct immune/neurological regulatory peptides such as Selank and Na-Selank.
Unmodified Semax exhibits high affinity and rapid receptor interaction but suffers from rapid enzymatic cleavage by serum aminopeptidases, limiting its half-life in fluid assays. Na Semax mitigates N-terminal aminopeptidase degradation through its acetyl cap, whereas Semax Amidate protects against C-terminal carboxypeptidases. When comparing these compounds to Selank analogs—which derive from the endogenous tetrapeptide tuftsin—Na Semax acts predominantly via BDNF upregulation and dopaminergic/serotonergic pathway modulation, whereas Selank variants primarily influence GABAergic transmission and immune-modulating pathways.
Understanding these structural and functional divergences allows laboratories browsing our comprehensive catalog of research peptides to select the precise molecular tool necessary for their specific receptor binding or expression profiling experiments.
The stability of synthetic peptides in biological matrices is a critical variable in experimental design. Unmodified short-chain peptides are typically degraded within minutes when exposed to serum, plasma, or tissue homogenates due to pervasive endo- and exopeptidase activity.
In vitro degradation assays measuring peptide recovery via reversed-phase high-performance liquid chromatography (RP-HPLC) demonstrate that N-terminal acetylation significantly delays initial cleavage events. By blocking the free alpha-amino group, Na Semax prevents exopeptidases from initiating N-terminal trimming. This increased metabolic stability allows researchers to execute longer-duration cell culture experiments without requiring continuous re-dosing or rapid solvent replenishment.
This structural enhancement also influences pharmacokinetic profiling in preclinical animal models, yielding altered area-under-the-curve (AUC) values and extended terminal elimination half-lives compared to parent ACTH(4-10) sequence fragments.
Na Semax is supplied as a lyophilized (freeze-dried) powder to maintain maximum chemical stability during transit and storage. Lyophilization removes residual moisture, preventing hydrolytic degradation of the peptide backbone.
Reconstitution must be performed under sterile laboratory conditions inside a laminar flow hood. The choice of solvent depends on the intended experimental design: standard cell-culture assays typically utilize sterile, endo-free Phosphate-Buffered Saline (PBS, pH 7.4) or sterile Water for Injection (WFI). For non-clinical preparations requiring extended liquid stability, 0.9% bacteriostatic sodium chloride containing 0.9% benzyl alcohol may be selected.
When introducing solvent into the vial, direct high-velocity stream impact on the lyophilized cake should be avoided. Instead, allow the liquid to flow gently down the inner glass wall of the vial, followed by gentle swirling or slow inversion. Mechanical agitation, vigorous shaking, or sonication must be strictly avoided, as shear forces can disrupt peptide tertiary conformation or cause aggregation.
Proper temperature control is essential for maintaining the analytical integrity of Na Semax samples over time. Lyophilized peptides should be stored in a dark, temperature-controlled environment. For short-term storage (under 30 days), desiccated storage at 2°C to 8°C is acceptable; for long-term storage (up to 24 months), vials should be maintained at -20°C or -80°C.
Once reconstituted into solution, the chemical stability of Na Semax decreases significantly. Liquid aliquots should be used immediately or stored at -20°C or -80°C to prevent hydrolysis and oxidation. Repeated freeze-thaw cycles must be avoided, as phase changes induce mechanical stress on the peptide backbone and lead to precipitation or degradation.
Researchers should aliquot reconstituted solutions into single-use, low-binding microcentrifuge tubes to prevent peptide loss via non-specific adsorption to plastic surfaces. Furthermore, exposure to direct light and elevated temperatures must be minimized, particularly given the presence of methionine residues, which are sensitive to oxidation.
To ensure experimental reproducibility, researchers require absolute purity and lot-to-lot consistency. PX1 Research subjects every synthesis lot of Na Semax to rigorous analytical validation prior to distribution.
Purity is verified using Reversed-Phase High-Performance Liquid Chromatography (RP-HPLC). The resulting chromatogram must demonstrate a primary peak corresponding to Na Semax exceeding 98.0% total peak area, verifying the absence of truncated sequences, deletion peptides, or synthesis reagents. Molecular mass and sequence identity are confirmed using Electrospray Ionization Mass Spectrometry (ESI-MS), verifying that the observed mass-to-charge ratio matches the theoretical molecular weight.
In addition to chemical purity, biological contaminants must be quantified. Every batch undergoes Limulus Amebocyte Lysate (LAL) testing to confirm endotoxin levels remain below strictly controlled laboratory thresholds (<0.01 EU/μg). For high-throughput screening or multi-center research projects, verification documentation can be accessed via our wholesale laboratory portal.
Experimental reproducibility in peptide research depends directly on chemical purity, lack of cross-contaminants, and precise manufacturing control. Low-purity compounds introduce uncontrolled variables, leading to erratic cellular responses, baseline noise in binding assays, and unrepeatable data.
PX1 Research synthesizes all compounds in USA-based, GMP-compliant facilities adhering to ISO 9001 and ISO 17025 laboratory quality management systems. Every shipment includes a lot-specific Certificate of Analysis (COA) documenting RP-HPLC purity profiles, mass spec verification, and endotoxin assay results.
Orders placed by research institutions ship same-day (Monday through Friday) directly from state-of-the-art dispatch centers located in California and Arizona, ensuring minimal transit times and thermal protection for temperature-sensitive research compounds.
What is the structural difference between Semax and Na Semax?
Semax is a heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro. Na Semax contains an added N-terminal acetyl group (CH3CO-), which neutralizes the positive charge on the N-terminal amine, increases molecular lipophilicity, and provides steric resistance against aminopeptidase enzymes.
How does N-terminal acetylation affect peptide stability in laboratory biofluids?
N-terminal acetylation prevents exopeptidases from recognizing and cleaving the N-terminal amino acid. In vitro degradation studies demonstrate that acetylated variants like Na Semax exhibit an extended half-life in serum and tissue homogenates compared to unmodified sequences.
What molecular pathways are primarily investigated using Na Semax?
Na Semax is investigated primarily in neurotrophic research focused on BDNF (Brain-Derived Neurotrophic Factor) and TrkB receptor expression, CREB transcription factor activation, and neuroinflammatory responses following hypoxic or ischemic stress.
How should lyophilized Na Semax be stored upon receipt?
Lyophilized Na Semax should be stored in a desiccated container at -20°C for standard research timelines, or -80°C for long-term storage. Vials stored at 2°C to 8°C should be reconstituted within 30 days.
What solvent is recommended for reconstituting Na Semax for in vitro assays?
Sterile Phosphate-Buffered Saline (PBS, pH 7.4) or sterile endotoxin-free water (WFI) is recommended for acute cell culture work. For extended liquid stability where antimicrobial preservation is required, 0.9% bacteriostatic sodium chloride may be used.
What analytical tests are provided with PX1 Research Na Semax?
Every lot of Na Semax is supplied with a lot-specific Certificate of Analysis (COA) containing Reversed-Phase High-Performance Liquid Chromatography (RP-HPLC) purity analysis, Electrospray Ionization Mass Spectrometry (ESI-MS) identity verification, and LAL endotoxin assay data.
What is the purity threshold for PX1 Research Na Semax?
PX1 Research guarantees a minimum chemical purity of >98.0% as determined by RP-HPLC, ensuring minimal baseline noise and consistent kinetic data in experimental protocols.
Is Na Semax approved for human consumption or clinical administration?
No. Na Semax is supplied strictly as a research compound intended exclusively for in vitro, biochemical, and preclinical laboratory applications. It is not approved for human, clinical, veterinary, or therapeutic use.
All products are sold strictly for laboratory and research use only. Not for human or veterinary use, diagnosis, treatment or consumption. Statements have not been evaluated by the FDA.